Results from several published studies have suggested that the DNA repair deficiency associated with BRCA mutations results in enhanced sensitivity to many chemotherapy agents, particularly higher response rates to platinum-based drugs, have occurred in both metastatic and neoadjuvant settings.4, 7 Only 13 patients in our cohort were treated with platinum-based adjuvant regimens for early breast cancer, including one patient with a BRCA1 mutation and one with BRCA2. The gene discussed is BRCA1; the disease is breast cancer.